SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 61.9% in December

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 155,400 shares, an increase of 61.9% from the November 30th total of 96,000 shares. Currently, 1.5% of the company’s shares are sold short. Based on an average daily volume of 725,400 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On SciSparc

An institutional investor recently bought a new position in SciSparc stock. Renaissance Technologies LLC bought a new stake in shares of SciSparc Ltd. (NASDAQ:SPRC) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned 5.59% of SciSparc as of its most recent filing with the SEC. 25.06% of the stock is currently owned by institutional investors.

SciSparc Trading Down 14.2 %

NASDAQ SPRC traded down $0.07 during mid-day trading on Friday, hitting $0.43. The company’s stock had a trading volume of 8,035,851 shares, compared to its average volume of 2,476,734. SciSparc has a 52-week low of $0.20 and a 52-week high of $6.78. The stock’s fifty day simple moving average is $0.24 and its two-hundred day simple moving average is $0.39.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.